Sutro Biopharma (STRO) EBITDA (2017 - 2025)

Sutro Biopharma's EBITDA history runs 9 years deep, the most recent figure standing at -$38.0 million for Q4 2025.

• In Q4 2025, EBITDA rose 41.69% year-over-year to -$38.0 million; the TTM figure through Dec 2025 stood at -$158.4 million (up 33.59% YoY), while the FY2025 annual figure was -$158.4 million, up 33.59% from the prior year.
• EBITDA came in at -$38.0 million for Q4 2025 at Sutro Biopharma, up from -$48.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $43.2 million in Q4 2023 to a low of -$68.5 million in Q1 2025.
• A 5-year average of -$35.7 million and a median of -$40.7 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 187.67% in 2023 and plunged 251.23% in 2024, its largest moves.
• Sutro Biopharma's EBITDA stood at -$35.0 million in 2021, then slumped by 40.49% to -$49.2 million in 2022, then surged by 187.67% to $43.2 million in 2023, then slumped by 251.23% to -$65.3 million in 2024, then jumped by 41.69% to -$38.0 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$38.0 million, -$48.5 million, and -$3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison